Picture of IX Biopharma logo

42C IX Biopharma Cashflow Statement

0.000.00%
sg flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Annual cashflow statement for IX Biopharma, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.

2021
June 30th
2022
June 30th
2023
June 30th
2024
June 30th
2025
June 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-8.23-4.6-9.62-10.8-10.1
Depreciation
Amortisation
Non-Cash Items-1.576.650.9332.793.9
Unusual Items
Other Non-Cash Items
Changes in Working Capital0.4030.0080.0930.5881.62
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Payable / Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities-8.353.12-7.66-6.55-3.76
Capital Expenditures-0.553-0.2-0.695-0.285-0.201
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0.046-5.4201.340
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-0.507-5.62-0.6951.06-0.201
Financing Cash Flow Items0.448-0.202-0.311-0.286-0.593
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities109.791.420.7243.12
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash1.117.32-6.98-4.77-0.828